Ovarian Cancer
Are patient-reported outcomes (PROs) similar in the placebo and the niraparib groups, suggesting that over the course of treatment niraparib does not adversely affect patients’ quality of life? Results of the PRIMA/ENGOT-OV26/GOG-3012 trial begin to elucidate the answer to this question. Read More ›
Combination treatment is even more effective in women with ovarian cancer with BRCA mutations or homologous recombination deficiency (HRD)-positive tumors. Read More ›
The RESPONSE study will help characterize patient characteristics and regional specific therapeutic management strategies adopted in 7 countries to better understand poly (ADP-ribose) polymerase (PARP) inhibitor use and its impact on outcomes. Read More ›
An analysis of phase 3 data from ARIEL3 was reviewed, providing insight into treatment-emergent adverse events (AEs) in patients receiving maintenance therapy with rucaparib for ovarian cancer. Read More ›
An investigation of whether adding a maintenance therapy regimen of olaparib combined with bevacizumab provided a benefit beyond first progression in patients with newly diagnosed advanced high‐grade ovarian carcinoma. Read More ›
A recent study explores niraparib’s efficacy, safety, and effect on quality of life in compared age-groups. Read More ›
In patients with high-grade ovarian cancer harboring BRCA mutations and a confirmed response to rucaparib, BRCA homozygous deletion or rearrangement was associated with a significantly longer duration of response. Read More ›
Despite substantial rates of intraoperative tumor spillages, patients with ovarian germ cell tumors (OGCTs) had an excellent prognosis, and adjuvant chemotherapy showed evidence of preventing disease recurrence. Read More ›
Is subsequent chemotherapy less effective for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer who have been treated with olaparib as maintenance therapy? Here we discuss the latest findings from the SOLO2/ENGOT Ov-21 clinical trial. Read More ›
Due to a variety of factors, first-line therapy with atezolizumab failed to demonstrate significant activity in patients with newly diagnosed stage III or stage IV ovarian cancer. Read More ›